Diagnostic accuracy of
Aged
Dimensional Measurement Accuracy
Gallium Radioisotopes
/ pharmacology
Health Care Surveys
Humans
Male
Middle Aged
Multiparametric Magnetic Resonance Imaging
Positron Emission Tomography Computed Tomography
Prostate
/ diagnostic imaging
Prostate-Specific Antigen
/ analysis
Prostatectomy
Prostatic Neoplasms
/ diagnostic imaging
ROC Curve
Radiopharmaceuticals
/ pharmacology
Reproducibility of Results
Sensitivity and Specificity
PSMA
#PCSM
#ProstateCancer
PET-CT
diagnostic imaging
mpMRI
prostate cancer
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
10
7
2019
medline:
23
6
2020
entrez:
10
7
2019
Statut:
ppublish
Résumé
To evaluate the ability of prostate-specific membrane antigen (PSMA)-positron-emission tomography (PET)/computed tomography (CT) to detect intermediate-grade intra-prostatic prostate cancer (PCa), and to determine if PSMA-PET improves the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI). A total of 56 consecutive patients with International Society of Urological Pathology (ISUP) grade 2-3 PCa after radical prostatectomy, who underwent both mpMRI and PSMA-PET CT (hereafter PSMA-PET) preoperatively, were enrolled in this study. The accuracy of PSMA-PET, mpMRI alone, and the two procedures in combination was analysed for identifying ISUP grades 1-3 within a 12-segment model. The accuracy of a combined predictive model (PSMA-PET and mpMRI) was determined. Receiver-operating characteristic curve analysis to determine the optimal standardized uptake value (SUV On a per-patient basis, the sensitivities for PSMA-PET and mpMRI in identifying ISUP grades 2-3 PCa were 100% and 97%, respectively. Assessing ISUP grade ≥2 PCa using a 12-segment analysis, PSMA-PET demonstrated greater diagnostic accuracy (area under the curve), sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV), with values of 0.91, 88%, 93%, 95% and 85%, respectively, than did mpMRI (Prostate Imaging Reporting and Data System [PI-RADS] 3-5), at 0.79, 68%, 91%, 87%, and 75%, respectively. When used in combination (PSMA-PET and mpMRI PIRADS 4-5), sensitivity, specificity, NPV and PPV were 92%, 90%, 96% and 81%, respectively. The sensitivity for both techniques reduced markedly when assessing ISUP grade 1 PCa (18% for PSMA-PET, 10% for mpMRI). An SUV PSMA-PET is accurate in detecting segments containing intermediate-grade intra-prostatic PCa (ISUP grade ≥ 2), compared with and complementary to mpMRI. By contrast the detection rate for ISUP grade 1 disease for both PSMA-PET and mpMRI was low.
Substances chimiques
Gallium Radioisotopes
0
Radiopharmaceuticals
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-49Informations de copyright
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Références
Futterer JJ, Briganti A, De Visschere P et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 2015; 68: 1045-53
Ahmed HU, El-Shater Bosaily A, Brown LC et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 6736: 1-8
Kasivisvanathan V, Rannikko AS, Borghi M et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378: 1767-77
Hamdy FC, Donovan JL, Lane JA et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-24
Scheltema MJ, Tay KJ, Postema AW et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol 2017; 35: 695-701
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-61
van Leeuwen PJ, Emmett L, Ho B et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017; 119: 209-15
Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20
Kesch C, Vinsensia M, Radtke JP et al. Intraindividual comparison of (18)F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study. J Nucl Med 2017; 58: 1805-10
Barentsz JO, Weinreb JC, Verma S et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 2016; 69: 41-9
Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16-40
Quinn DI, Henshall SM, Haynes AM et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001; 19: 3692-705
Shakir N, Walton-Diaz A, Rais-Bahrami S et al. Multiparametric prostate MRI and MRI/ultrasound fusion biopsy as tools to follow prostate cancer progression for men on active surveillance. J Clin Oncol 2014; 32(4_suppl): 63
Eineluoto JT, Järvinen P, Kenttämies A et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS ONE 2017; 12: e0189272
Eiber M, Weirich G, Holzapfel K et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 2016; 70: 829-36
Chen M, Zhang Q, Zhang C, Zhao X, Marra G. Combination of 68 Ga-PSMA PET/CT and multiparameter MRI improves the detection of clinically significant prostate cancer: a lesion by lesion analysis. J Nucl Med 2018. http://doi.org/10.2967/jnumed.118.221010
Rhee H, Thomas P, Shepherd B et al. New technology and techniques prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. J Urol 2016; 196: 1261-7
Zamboglou C, Drendel V, Jilg CA et al. Comparison of 68 Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017; 7: 228-37
Ross JS, Sheehan CE, Fisher HAG et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-62
Israeli RS, Miller WHJ, Su SL et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54: 6306-10
Wright GLJ, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995; 1: 18-28
Perner S, Hofer MD, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701
Minner S, Wittmer C, Graefen M et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. Prostate 2011; 71: 281-8
Lopci E, Saita A, Lazzeri M et al. 68Ga-PSMA Positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol 2018; 200: 95-103
Valerio M, Donaldson I, Emberton M et al. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol 2015; 68: 8-19
Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006; 50: 1163-75
Yaxley AJ, Yaxley JW, Thangasamy IA, Ballard E, Pokorny MR. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions. BJU Int 2017; 120(Suppl): 43-50
Turkbey B, Mani H, Aras O et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013; 268: 144-52
Koerber SA, Utzinger MT, Kratochwil C et al. (68)Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med 2017; 58: 1943-8
Bratan F, Niaf E, Melodelima C et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 2013; 23: 2019-29
Wolters T, Roobol MJ, Van Leeuwen PJ et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2010; 185: 121-5
Tran M, Thompson J, Böhm M et al. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy. BJU Int 2016; 117: 48-54
Graser A, Heuck A, Sommer B et al. Per-Sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. Am J Roentgenol 2007; 188: 84-90
Zeps N, Davis ID, Mark S. Good clinical practice can and must include comparative effectiveness research. BJU Int 2018; 122(Suppl): 7-8
Rutledge AB, McLeod N, Mehan N et al. A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer. BJU Int 2018; 121: 22-7